XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 12.80%1.23B | 14.14%331M | 20.00%336M | 13.17%318M | 2.13%240M | 18.43%1.09B | -1.36%290M | 6.06%280M | 30.09%281M | 64.34%235M |
Net income from continuing operations | -39.19%211M | -150.55%-46M | 7.96%122M | -7.89%70M | -2.99%65M | 5.15%347M | -7.14%91M | 11.88%113M | 4.11%76M | 15.52%67M |
Operating gains losses | 213.83%107M | 1,070.59%165M | 40.00%-15M | 25.93%-20M | 8.00%-23M | -161.11%-94M | 0.00%-17M | -400.00%-25M | -440.00%-27M | -177.78%-25M |
Depreciation and amortization | 6.75%806M | 11.98%215M | 5.61%207M | 3.17%195M | 6.18%189M | 19.65%755M | 10.98%192M | 18.79%196M | 23.53%189M | 27.14%178M |
Deferred tax | -33.71%59M | -95.83%2M | 76.19%37M | -35.29%11M | 200.00%9M | 7.23%89M | 860.00%48M | -40.00%21M | -55.26%17M | -40.00%3M |
Other non cash items | 240.00%17M | 300.00%4M | 600.00%5M | 100.00%4M | 33.33%4M | -44.44%5M | -75.00%1M | -150.00%-1M | 100.00%2M | 50.00%3M |
Change In working capital | 37.37%-62M | 27.27%-32M | 4.08%-47M | 1,800.00%38M | -162.50%-21M | 44.69%-99M | -833.33%-44M | 14.04%-49M | 103.33%2M | 88.24%-8M |
-Change in receivables | 36.73%-62M | 173.68%14M | 1.82%-54M | 59.46%-15M | -153.85%-7M | 43.02%-98M | -18.75%-19M | 24.66%-55M | 38.33%-37M | 156.52%13M |
-Change in payables and accrued expense | 23.81%26M | -316.67%-25M | 110.00%21M | 5.56%38M | 57.89%-8M | 162.50%21M | -122.22%-6M | -47.37%10M | 3,700.00%36M | 48.65%-19M |
-Change in other current assets | -18.18%-26M | -10.53%-21M | -250.00%-14M | 400.00%15M | -200.00%-6M | -46.67%-22M | -280.00%-19M | -33.33%-4M | 200.00%3M | 75.00%-2M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 12.80%1.23B | 14.14%331M | 20.00%336M | 13.17%318M | 2.13%240M | 18.43%1.09B | -1.36%290M | 6.06%280M | 30.09%281M | 64.34%235M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 4.43%-1.51B | -4.28%-268M | -37.82%-543M | 15.66%-404M | 34.37%-296M | 6.00%-1.58B | 29.78%-257M | 10.86%-394M | 9.11%-479M | -29.97%-451M |
Capital expenditure reported | -3.21%-161M | 8.11%-34M | -33.33%-56M | 6.82%-41M | 9.09%-30M | -50.00%-156M | -68.18%-37M | 22.22%-42M | -193.33%-44M | -153.85%-33M |
Net PPE purchase and sale | 23.47%-750M | -64.75%-201M | 28.08%-210M | 22.73%-221M | 57.86%-118M | 5.77%-980M | 54.81%-122M | -10.61%-292M | -14.40%-286M | -9.38%-280M |
Net business purchase and sale | -39.53%-600M | 66.33%-33M | -361.67%-277M | -5.97%-142M | -7.25%-148M | 16.50%-430M | -32.43%-98M | 51.61%-60M | 45.08%-134M | -89.04%-138M |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | 34.78%-15M | --0 | --0 | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 4.43%-1.51B | -4.28%-268M | -37.82%-543M | 15.66%-404M | 34.37%-296M | 6.00%-1.58B | 29.78%-257M | 10.86%-394M | 9.11%-479M | -29.97%-451M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -41.60%299M | -266.67%-121M | 88.51%279M | -52.31%93M | -76.24%48M | -34.78%512M | -147.83%-33M | -19.57%148M | -42.65%195M | 5.21%202M |
Net issuance payments of debt | -46.13%390M | -3,366.67%-104M | 81.10%297M | -56.57%119M | -73.01%78M | -26.65%724M | -102.04%-3M | -37.16%164M | -23.03%274M | 29.60%289M |
Net common stock issuance | --0 | --0 | --0 | --0 | --0 | -4.35%-120M | 79.03%-13M | --0 | ---63M | ---44M |
Cash dividends paid | -5.48%-77M | -11.76%-19M | -5.56%-19M | -5.56%-19M | 0.00%-20M | -7.35%-73M | 0.00%-17M | -5.88%-18M | -5.88%-18M | -17.65%-20M |
Proceeds from stock option exercised by employees | 0.00%7M | 100.00%2M | -50.00%1M | 0.00%2M | 0.00%2M | 75.00%7M | 0.00%1M | 100.00%2M | 100.00%2M | 100.00%2M |
Net other financing activities | 19.23%-21M | --0 | --0 | ---9M | 52.00%-12M | -13.04%-26M | ---1M | --0 | --0 | -66.67%-25M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -41.60%299M | -266.67%-121M | 88.51%279M | -52.31%93M | -76.24%48M | -34.78%512M | -147.83%-33M | -19.57%148M | -42.65%195M | 5.21%202M |
Net cash flow | ||||||||||
Beginning cash position | 31.48%71M | 100.00%142M | 89.19%70M | 57.50%63M | 31.48%71M | 54.29%54M | 24.56%71M | -28.85%37M | 73.91%40M | 54.29%54M |
Current changes in cash | -23.53%13M | ---58M | 111.76%72M | 333.33%7M | 42.86%-8M | -15.00%17M | --0 | 466.67%34M | -110.34%-3M | -16.67%-14M |
Effect of exchange rate changes | ---1M | ---1M | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
End cash Position | 16.90%83M | 16.90%83M | 100.00%142M | 89.19%70M | 57.50%63M | 31.48%71M | 31.48%71M | 24.56%71M | -28.85%37M | 73.91%40M |
Free cash flow | 104.10%16M | -93.94%2M | 96.86%-5M | 92.54%-10M | 122.31%29M | -9.86%-390M | 160.00%33M | -112.00%-159M | -97.06%-134M | 17.20%-130M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |